Department of Neurology, National Neuroscience Institute, Singapore, Singapore.
Department of Neurology, National Neuroscience Institute, Singapore, Singapore; Neuroscience and Behavioral Disorders Program, Duke-NUS Medical School, Singapore, Singapore.
Cell Rep Med. 2022 Oct 18;3(10):100778. doi: 10.1016/j.xcrm.2022.100778.
Jennings et al. reported that LRRK2 inhibitors can reduce kinase activity and improve lysosomal function with minor adverse effects in both animal models and human subjects. The findings provide proof of principle for LRRK2 inhibitor as a Parkinson's disease therapeutic option.
詹宁斯等人报告称，LRRK2 抑制剂可降低激酶活性并改善溶酶体功能，且在动物模型和人类受试者中仅有轻微不良反应。这些发现为 LRRK2 抑制剂作为帕金森病治疗选择提供了原理证明。
